- Published at
- by themarketherald.com.au
mixed
mixed
HotCopper Highlights for Week 10 – What got the forums going this week
Good Afternoon and welcome to the weekly HotCopper Highlights wrap for Week 10, I’m Jonathon Davidson. Let’s get into it.
News for Mesoblast Limited (MESO)
- Published at
- by benzinga.com
positivepositiveMesoblast Added to S&P/ASX 200 INDEX - Mesoblast (NASDAQ:MESO)
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P Dow Jones- Published at
- by themarketherald.com.au
mixedmixedASX Market Close: New tariffs; OPEC+ & iron ore help to tank market
Another depressing day for Oz. The culprit? Wall Street's worst night YTD, OPEC+ output boost, iron ore tumble and Trump.- Published at
- by seekingalpha.com
positivepositiveMesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO) Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive Officer...- Published at
- by gurufocus.com
positivepositiveHalf Year 2025 Mesoblast Ltd Earnings Presentation Transcript
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMSB.AX - Mesoblast LtdHalf Year 2025 Mesoblast Ltd Earnings PresentationFeb 26, 2025 / 10:00PM- Published at
- by manilatimes.net
positivepositive- Published at
- by zacks.com
positivepositiveMesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Mesoblast Limited (MESO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveDr. Gregory George MD PhD Joins Mesoblast Board
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today- Published at
- by manilatimes.net
mixedmixedPresenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
**media[544182]**- Published at
- by manilatimes.net
positivepositiveRyoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
**media[540421,540422,540423]**- Published at
- by insidermonkey.com
positivepositiveIs Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?
We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Mesoblast Limited (NASDAQ:MESO) stands against the other long term ASX...- Published at
- by insidermonkey.com
positivepositiveIs Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?
We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Mesoblast Limited (NASDAQ:MESO) stands against other best ...- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by themarketherald.com.au
positivepositiveTelix clocks +150% year-on-year returns as radiopharma acquisition well received
Telix Pharmaceuticals (ASX:TLX) has joined a somewhat quiet cohort of ASX biotech companies having a pretty good run lately.- Published at
- by benzinga.com
positivepositiveTop 2 Health Care Stocks That Are Ticking Portfolio Bombs - Mesoblast (NASDAQ:MESO), Sana Biotechnology (NASDAQ:SANA)
As of Jan. 10, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading de...- Published at
- by rttnews.com
mixedmixedAsian Markets Track Wall Street Lower
Asian stock markets are trading mostly higher on Tuesday, following the broadly negative cues from Wall Street overnight, as traders are worried US President-elect Donald Trump's protectionist trade policies will likely push up inflation next year.- Published at
- by seekingalpha.com
positivepositiveMesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall (NASDAQ:MESO)
Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US commercialization efforts.- Published at
- by investing.com
positivepositiveMesoblast Stock Soars to 52-Week High, Hits $19.15 By Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $19.15